Reversal of Valvular Calcification in Bicuspid Aortic Valve
Abstract
Fiscal Year 2018 Peer Reviewed Medical Research Program: Congenital Heart Disease Area of Encouragement: Research to design and implement disease-in-a-dish and/or microfluidic models with an established phenotype to increase the efficacy of finding novel and/or innovative drug targets, screen existing drugs, perform cardiotoxicity testing, and/or uncover pathogenesis. Bicuspid aortic valve, an aortic valve with two leaflets instead of the usual three, is the most common congenital heart disease. Patients with bicuspid aortic valve frequently develop narrowing of aortic valve, often at a young age. Over time, this can lead to chest pain, syncope, and heart failure, which if not treated surgically by replacing the valve with an artificial valve, can lead to death within a few years. There is currently no effective medical treatment to prevent or reverse aortic valve calcification. Using a novel methodology, here we seek to identify new ways and new agents that can potentially reverse aortic valve calcification in cell culture and validate selected agents in a mouse model of the disease. If successful, the project will lead to a new noninvasive approach to treatment of bicuspid aortic valve calcification and ultimately decrease the impact of the disease in the population.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Mar 05, 2019
- Source ID
- W81XWH1910044
Entities
People
- Mehran M Sadeghi
Organizations
- United States Army
- Yale University